drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (autologous CAR T cells)
drug_description
Autologous BCMA-directed CAR T-cell therapy; patient T cells are engineered to express a CAR targeting BCMA to eliminate BCMA+ plasmablasts/long-lived plasma cells and reduce autoantibody-mediated platelet destruction.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically modified to express a chimeric antigen receptor targeting BCMA; after infusion they recognize and kill BCMA-positive plasmablasts and long-lived plasma cells, depleting autoantibody-producing cells and reducing platelet-directed autoimmunity.
drug_name
PRG-1801
nct_id_drug_ref
NCT06519565